Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Codexis Inc. (CDXS:NASDAQ), powered by AI.
Codexis Inc. is currently trading at $2.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Codexis Inc. on Alpha Lenz.
View Codexis Inc.'s valuation metrics on Alpha Lenz.
“Codexis Inc.'s ROE is -74.9%. Explore profitability and growth together.”
Ask for details →Codexis Inc. operates within the biotechnology sector, specializing in the engineering of enzymes and proteins to serve diverse industries. The company's primary function is to harness its proprietary technology platforms for the creation of specialized biocatalysts. These biocatalysts are instrumental in improving the efficiency and sustainability of chemical processes, particularly in pharmaceuticals and sustainable manufacturing. Codexis's technology is applied in the development of novel therapeutics, enhanced drug manufacturing processes, and the production of food and industrial chemicals with reduced environmental impact. Headquartered in Redwood City, California, the organization holds a prominent position in the market as a pioneer in protein engineering. Through partnerships with major pharmaceutical companies and other industry leaders, Codexis significantly contributes to the innovation landscape in enzyme application, driving advancements in health-based solutions and sustainable development across multiple sectors.
“Codexis Inc.'s ROE is -74.9%. Explore profitability and growth together.”
Ask for details →Codexis Inc. (ticker: CDXS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 188 employees.
The current price is $2.4 with a P/E ratio of -x and P/B of -x.
ROE is -74.88% and operating margin is -54.46%. Annual revenue is $70M.